bexarotene has been researched along with methotrexate in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beyeler, M; Dummer, R | 1 |
| Bagot, M | 1 |
| Dalle, S; Thomas, L | 1 |
| Arulogun, S; Eaton, E; Gambell, P; Lade, S; McCormack, C; Prince, HM; Ryan, G | 1 |
| Fleischer, AB; Kannangara, AP; Levitan, D | 1 |
| Altiner, A; Berger, E; Chu, J; Latkowski, JA; Patel, R; Sanders, S | 1 |
| Hall, AG; Marshall, GD; Morris, AE | 1 |
| Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S | 1 |
| Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J | 1 |
| Geskin, L; Malone, DC | 1 |
| Briones, J; Espeso, M; Martín, A; Mozos, A; Novelli, S; Sánchez, JJ | 1 |
| Elsea, D; Lilley, C; Lisano, J; Liu, J; Savage, KJ; Yu, KS | 1 |
5 review(s) available for bexarotene and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Standard and experimental therapy of cutaneous T-cell lymphoma].
Topics: Adrenal Cortex Hormones; Aminoquinolines; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell; Methotrexate; Photopheresis; Prednisone; PUVA Therapy; Radioisotope Teletherapy; Radiotherapy Dosage; Radiotherapy, High-Energy; Recombinant Proteins; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine | 2003 |
Mycosis fungoides stage IB progressing to cutaneous tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Black or African American; Disease Progression; Female; Humans; Interferon-alpha; Methotrexate; Mycosis Fungoides; Skin Neoplasms; Skin Pigmentation; Tetrahydronaphthalenes; Ultraviolet Therapy | 2011 |
Not all that itches is urticaria.
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Bexarotene; Biopsy, Needle; Black or African American; Diagnosis, Differential; Education, Medical, Continuing; Eosinophilia; Female; Humans; Ki-1 Antigen; Methotrexate; Middle Aged; Mycosis Fungoides; Prednisone; Pruritus; Skin Neoplasms; Tetrahydronaphthalenes; Urticaria | 2012 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2014 |
10 other study(ies) available for bexarotene and methotrexate
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunologic Factors; Interferon-alpha; Methotrexate; Middle Aged; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes | 2008 |
Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bexarotene; Drug Resistance, Neoplasm; Humans; Interferons; Male; Methotrexate; Mycosis Fungoides; PUVA Therapy; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2008 |
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cohort Studies; Disease-Free Survival; Female; Humans; Interferon-alpha; Male; Methotrexate; Middle Aged; Photopheresis; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2008 |
Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Retrospective Studies; Risk Assessment; Sex Factors; Skin Neoplasms; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Bexarotene; Cost-Benefit Analysis; Diphtheria Toxin; Humans; Hydroxamic Acids; Interferon-alpha; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Methotrexate; Photopheresis; Recombinant Fusion Proteins; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; Vorinostat | 2018 |
Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Cyclophosphamide; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Palliative Care; Prednisone; Referral and Consultation; Retrospective Studies; Sezary Syndrome; Skin Neoplasms; Spain; Survival Analysis; Transplantation, Homologous; Vincristine | 2020 |
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Topics: Bexarotene; Brentuximab Vedotin; Canada; Cost-Benefit Analysis; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Methotrexate; Neoplasm Recurrence, Local; Physicians; Skin Neoplasms | 2023 |